FDA Transparency Could Tank Pharma Stocks
New disclosure proposals from the FDA will mean less spin and more stock-moving information surrounding the drug approval process.
The FDA announced Wednesday that its Transparency Task Force has come up with 21 proposals that could finally make the FDA more readily available to the average person. If you've ever been on the agency's website, you know that its current iteration is far from user-friendly.
The proposals, based on user feedback after two public meetings, are meant to help consumers and others better understand the process the FDA takes when making decisions. The agency and the task force will be accepting public comment on the proposals and will decide in late July which of them are going to stick.
The task force's ideas address the lack of usability on the FDA website, as well as corral information from other regulatory websites that might relate to drug products (like US Justice Dept. cases), and most importantly would make public disclosures related to drug approval, rejection, and evaluation.
That last part is incredibly important and could have pharmaceutical and biotech companies scrambling to find a way to keep this from happening. The new proposals would allow the FDA to disclose the contents of Complete Response Letters -- a practice that could devastate a company stock price. Complete Response Letters are issued by the FDA to a company when a drug is rejected. In those letters the agency tells the company why a drug wasn't approved and what steps, if any, can be taken to reach approval. This is currently a private matter between the agency and the company; it's at the company's discretion to release the letter -- something that's virtually unheard of.
The proposals extend further to the disclosure of when the FDA has put a hold on a clinical trial, when a drug development application is withdrawn by the sponsor, whether it agrees with published reports about products with approvals pending, and why it does not approve a marketing application. This transparency would also extend to disclosure of when the FDA inspects a plant – including what plant and what sort of violations were found.
It's somewhat shocking and amazing that the agency doesn't disclose these things already. Any logical person would say this information is of the utmost importance to a consumer who's buying these drugs and devices. For example, disclosures of plant inspections could have alerted the public well in advance of the problems that have been recurring at the McNeil unit of Johnson & Johnson (JNJ) -- making the recent recall of children's medication less dangerous. Further transparency regarding FDA investigations into side effects of a drug could keep many people from having to go through an experience like that of Merck's (MRK) Vioxx -- a situation that hurt a lot of people and spiraled out of control when the company failed to properly inform consumers.
Yet, while all of these proposals would bring about a more informed consumer who's better aware of the dangers that may be lurking in his or her medicine cabinet, it could have disastrous effects on the manufacturers and their stock prices. Sales of drugs like GlaxoSmithKline's (GSK) Avandia could have been greatly diminished if the discussions about heart problems caused by the drug had been made public without the PR spin of the pharmaceutical company.
Stock prices would also take catastrophic dives if investors were made aware that a company had withdrawn a drug application, or if the market found out that a clinical trial was being held up. Currently, pharmaceutical companies have the luxury of releasing this information on their own terms and timelines. This means that the public and the market reaction can be "handled" by public relations professionals who are skilled at downplaying these problems.
July is going to be an interesting time for the FDA and the entire pharmaceutical community. Future investors will need to be prepared for the affects a raw, spin-less flow of data can have on the companies that their portfolios depend upon.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.
Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Daily Recap Newsletter